PROK vs. IMTX, RLAY, AUTL, MESO, PRME, BCRX, RGNX, CRGX, SRRK, and HUMA
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Immatics (IMTX), Relay Therapeutics (RLAY), Autolus Therapeutics (AUTL), Mesoblast (MESO), Prime Medicine (PRME), BioCryst Pharmaceuticals (BCRX), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Scholar Rock (SRRK), and Humacyte (HUMA). These companies are all part of the "biological products, except diagnostic" industry.
Immatics (NASDAQ:IMTX) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
ProKidney has a net margin of 0.00% compared to ProKidney's net margin of -179.67%. Immatics' return on equity of 0.00% beat ProKidney's return on equity.
Immatics received 20 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 72.22% of users gave Immatics an outperform vote while only 66.67% of users gave ProKidney an outperform vote.
Immatics currently has a consensus price target of $16.00, suggesting a potential upside of 48.01%. ProKidney has a consensus price target of $9.50, suggesting a potential upside of 150.66%. Given Immatics' higher possible upside, analysts plainly believe ProKidney is more favorable than Immatics.
ProKidney has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immatics had 1 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Immatics and 10 mentions for ProKidney. Immatics' average media sentiment score of 0.77 beat ProKidney's score of 0.69 indicating that ProKidney is being referred to more favorably in the news media.
Immatics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
64.4% of Immatics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 45.0% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
ProKidney beats Immatics on 10 of the 17 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
